ANNALS OF MEDICAL AND SURGICAL DERMATOLOGY
Jul-Sept 2024, VOL. 2, ISSUE 3, pp 17-19
https://doi.org/10.61577/amsd.2024.1000015

RESEAPRO JOURNALS

REVIEW

OPEN ACCESS

Cutaneous lupus erythematosus: Immunologic mechanisms and current therapeutic approaches

Lucas Werth[1], Dennis Wenzel[2] and Hobart Filipe[3]

[1]Department of Dermatology, University of Utah School of Medicine, USA
[2]Dermatology Service, University of Utah School of Medicine, USA
[3]Department of Dermatology, University Hospital Bonn, Bonn, Germany

ABSTRACT

Cutaneous lupus erythematosus (CLE) is an autoimmune dermatologic condition that primarily affects the skin, constantly associated with systemic lupus erythematosus (SLE). It's characterized by distinct skin lesions, including erythematous pillars, photosensitivity, and the hallmark butterfly rash. The immunologic mechanisms bolstering CLE are complex, involving dysregulated vulnerable responses analogous as the product of autoantibodies (-dsDNA), abnormal activation of T- cells (particularly Th1 and Th17 cells), and type I interferon signaling. heritable factors, environmental triggers, and vulnerable system dysregulation play significant places in the pathogenesis of CLE. Current remedial approaches concentrate on topical corticosteroids, immunosuppressive agents like hydroxychloroquine, and birth antidotes analogous as belimumab. While these treatments offer symptom control, challenges remain, including treatment resistance and the need for personalized medicine. Advances in understanding the immunologic mechanisms of CLE are essential for developing further targeted antidotes. This review highlights the immunopathogenesis of CLE and examines the current remedial strategies, with an emphasis on the need for continued disquisition to meliorate treatment issues.

KEYWORDS

Cutaneous lupus erythematosus; Immunologic mechanisms; Autoimmune skin disease; T-cells; Type I interferon; Hydroxychloroquine; Belimumab

ARTICLE HISTORY

Received 05 July 2024;
Revised 25 July 2024;
Accepted 01 August 2024

Introduction

CLE is a habitual autoimmune skin condition that presents with a variety of dermatologic instantiations, ranging from mild rashes to more severe lesions that can lead to scarring. CLE can do as part of SLE or as an insulated complaint. It's characterized by vulnerable system dysregulation, where the body's vulnerable cells inaptly attack healthy skin towel [1]. The exact immunologic mechanisms behind CLE are complex, involving the activation of autoreactive T- cells, product of autoantibodies, and an imbalance in type I interferon signaling [2]. These vulnerable responses contribute to the characteristic skin lesions seen in CLE, similar as erythematous pillars and photosensitivity. While treatments for CLE primarily aim to control symptoms and reduce inflammation, managing the underpinning vulnerable dysfunction remains a challenge [3]. Current remedial approaches include topical corticosteroids, antimalarial medicines like hydroxychloroquine, and birth curatives similar as belimumab. Despite these advances, treatment resistance and the need for substantiated remedy persist, pressing the need for continued exploration to more understand CLE's immunology and ameliorate patient issues [4].

Immunologic Mechanisms of Cutaneous Lupus Erythematosus

The immunologic mechanisms of CLE are driven by complex relations between the ingrain and adaptive vulnerable systems. At the core of CLE pathology is vulnerable dysregulation, leading to the generation of autoreactive vulnerable cells and autoantibodies that target the skin and contribute to the development of skin lesions [5].

Activation of T- cells is central to CLE pathogenesis, particularly the involvement of T- coadjutor cells. Th1 and Th17 cells, which play vital places in autoimmune conditions, are hyperactive in CLE. These T- cells release cytokines similar as interferon- gamma (IFN- γ) and interleukin- 17 (IL- 17), which promote inflammation and the reclamation of other vulnerable cells to the skin, leading to towel damage and lesion conformation [6].

Type I interferons (IFNs), particularly IFN- α, are also critical in CLE. They're abnormally actuated in response to circulating vulnerable complexes containing autoantibodies, which deposit in the skin. This activation amplifies the seditious response and promotes the expression of interferon-stimulated genes (ISGs) in keratinocytes and other skin cells, contributing to the continuity of skin lesions [7].

Autoantibodies, similar asanti-dsDNA and anti- Ro/ SSA, are another hallmark of CLE. These antibodies fete and bind to nuclear antigens, forming vulnerable complexes that can deposit in the skin, driving complement activation and farther contributing to towel inflammation [8].

Clinical Manifestations and Diagnosis of Cutaneous Lupus Erythematosus (CLE)

CLE presents with a range of dermatologic instantiations, which can vary in inflexibility, appearance, and distribution. The primary types of CLE are discoid lupus erythematosus (DLE), SCLE, and acute cutaneous lupus erythematosus (ACLE) [9].

***Correspondence:** Dr. Lucas Werth, Department of Dermatology, University of Utah School of Medicine, USA, e-mail: werthlucas@yahoo.com

Discoid lupus erythematosus (DLE)

DLE is the most common form, characterized by well-terminated, red, scaled pillars with central atrophy and follicular plugging. These lesions generally appear on sun-exposed areas like the face, crown, and cognizance, and can beget endless scarring and hair loss [10].

Subacute cutaneous lupus erythematosus (SCLE)

manifests as annular or polycyclic lesions with a raised, erythematous border and central clearing. These lesions generally do on the upper torso, shoulders, and arms [11]. SCLE is frequently touched off by sun exposure and is associated with SLE.

Acute Cutaneous Lupus Erythematosus (ACLE)

ACLE is marked by the hallmark malar butterfly rash, which extends over the cheeks and ground of the nose, sparing the nasolabial crowds. Photosensitivity, where exposure to sun exacerbates the rash, is a crucial point opinion of CLE involves clinical evaluation, skin vivisection, and laboratory tests. A skin vivisection shows interface dermatitis, characterized by seditious changes at the dermo- epidermal junction. Blood tests frequently reveal antinuclear antibodies (Corpus), and specific autoantibodies similar as anti- Ro/ SSA and anti- La/ SSB may be elevated [12]. individual imaging and photo testing can also prop in attesting the opinion and assessing photosensitivity.

Current Remedial Approaches

The operation of CLE focuses on reducing inflammation, controlling complaint exertion, and precluding scarring, with curatives acclimatized to the inflexibility of the condition [13]. The primary treatment strategies include topical treatments, systemic curatives, and life variations.

- Topical Treatments For mild cases, topical corticosteroids are generally used to reduce inflammation and control localized lesions. Potent corticosteroids may be needed for more severe lesions, while milder steroids can be used for sensitive areas. also, topical calcineurin impediments (e.g., tacrolimus) are useful for facial lesions to avoid the side goods of dragged steroid use, similar as skin thinning [14].
- Systemic Treatments In more expansive or resistant cases, hydroxychloroquine (an antimalarial medicine) is the foundation of systemic remedy, reducing both skin inflammation and systemic lupus exertion [15]. It's generally well- permitted, however longterm use requires covering for retinal toxin. In cases where hydroxychloroquine is ineffective, methotrexate or azathioprine, which are immunosuppressive agents, may be employed to control complaint exertion.
- Birth curatives for cases with refractory CLE, birth agents like belimumab, which targets B- cell exertion, have shown pledge [16]. These agents help modulate the vulnerable system and reduce complaint flares. Rituximab and other biologics targeting specific vulnerable pathways may also be used in severe or resistant cases.
- Sun Protection and Lifestyle variations Cases with CLE are largely sensitive to ultraviolet (UV) light, so photoprotection is pivotal [17]. Broad- diapason sunscreens, defensive apparel, and avoidance of direct sun are essential in managing complaint flare- ups.

These remedial approaches aim to manage the vulnerable dysregulation in CLE and ameliorate patient issues, although challenges remain in managing severe or refractory cases.

Future Directions in Research and Treatment

Unborn exploration in CLE is concentrated on understanding the underpinning immunologic mechanisms to develop further targeted curatives. probing the part of type I interferons, B-cells, and T- cell subsets could lead to more precise treatments [18]. Birth curatives targeting these pathways, similar as JAK impediments or T- cell modulators, are promising. also, inheritable exploration will help identify biomarkers for early opinion and substantiated treatment strategies [19]. Advances in photoprotection and gene remedy may also ameliorate operation. Clinical trials exploring new immunomodulatory agents and combination curatives are critical to enhancing treatment issues for CLE cases.

Conclusions

Unborn exploration in CLE is concentrated on understanding the underpinning immunologic mechanisms to develop further targeted curatives. probing the part of type I interferons, B-cells, and T- cell subsets could lead to more precise treatments. Birth curatives targeting these pathways, similar as JAK impediments or T- cell modulators, are promising. also, inheritable exploration will help identify biomarkers for early opinion and substantiated treatment strategies. Advances in photoprotection and gene remedy may also ameliorate operation. Clinical trials exploring new immunomodulatory agents and combination curatives are critical to enhancing treatment issues for CLE cases.

Disclosure Statement

No potential conflict of interest was reported by the authors.

References

1. Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16(8):829-837. https://doi.org/10.1080/1744666X.2020.1805316
2. Y Fetter T, Braegelmann C, de Vos L, Wenzel J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front Med. 2022;9:915828. https://doi.org/10.3389/fmed.2022.915828
3. Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20:1-10. https://doi.org/10.1007/s11882-020-00906-8.
4. Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208-214. https://doi.org/10.1097/BOR.0000000000000704.
5. Zhou X, Yan J, Lu Q, Zhou H, Fan L. The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions. Scand J Immunol. 2021;93(1):e12933. https://doi.org/10.1111/sji.12933
6. Hu P, Wang M, Gao H, Zheng A, Li J, Mu D, et al. The role of helper T cells in psoriasis. Front Immunol. 2021;12:788940 https://doi.org/10.3389/fimmu.2021.788940
7. Greenberg EN, Marshall ME, Jin S, Venkatesh S, Dragan M, Tsoi LC, et al. Circadian control of interferon-sensitive gene expression in murine skin. Proc Natl Acad Sci. 2020;117(11):5761-5771. https://doi.org/10.1073/pnas.1915773117
8. Edwards G, Diercks GF, Seelen MA, Horvath B, Van Doorn MB,

https://doi.org/10.61577/amsd.2024.1000015

Damman J. Complement activation in autoimmune bullous dermatoses: a comprehensive review. Front Immunol. 2019; 10:1477. https://doi.org/10.3389/fimmu.2019.01477
9. Abernathy-Close L, Lazar S, Stannard J, Tsoi LC, Eddy S, Rizvi SM, et al. B cell signatures distinguish cutaneous lupus erythematosus subtypes and the presence of systemic disease activity. Front Immunol. 2021; 12:775353. https://doi.org/10.3389/fimmu.2021.775353
10. Ashraf E, Ghouse AN, Siddiqui S, Siddiqui S, Khan Z. Discoid lupus erythematosus: a cross-sectional study from the Sindh Institute of skin diseases, Karachi, Pakistan. Cureus. 2020;12(10). https://doi.org/10.7759/cureus.11201
11. Evans MS, Culton DA, Diaz LA, Googe PB, Morrell DS. Childhood pemphigus foliaceus presenting as a polycyclic eruption: Case report and review of the literature. Pediatr Dermatol. 2019;36(2):236-241. https://doi.org/10.1111/pde.13750
12. Agmon-Levin N, Dagan A, Peri Y, Anaya JM, Selmi C, Tincani A, et al. The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic. Clin Exp Rheumatol. 2017;35(6):929-935. Available at: https://cris.maastrichtuniversity.nl/en/publications/the-interaction-between-anti-rossa-and-anti-lassb-autoantibodies-
13. Joseph AK, Abbas LF, Chong BF. Treatments for disease damage in cutaneous lupus erythematosus: A narrative review. Dermatol Ther. 2021;34(5):e15034. https://doi.org/10.1111/dth.15034
14. Guenther L, Lynde C, Poulin Y. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg. 2019 ;23(4_suppl):27S-34S. https://doi.org/10.1177/1203475419857668
15. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X 211073001. https://doi.org/10.1177/1759720X211073001
16. Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208-214. https://doi.org/10.1097/BOR.0000000000000704
17. McGarry B, O'Kane D, McCourt C, Gormley GJ. 'More extraordinary than mundane…'A phenomenological analysis of the experiences of individuals living with CLE and their taking care in the sun. Lupus. 2020;29(13):1773-1780. https://doi.org/10.1177/0961203320958067
18. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10:365-381. https://doi.org/10.1016/j.jaut.2022.102865
19. Du Y, Liu M, Nigrovic PA, Dedeoglu F, Lee PY. Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. J Allergy Clin Immunol. 2023;151(3):607-618. https://doi.org/10.1016/j.jaci.2022.12.816

https://doi.org/10.61577/amsd.2024.1000015